Serum glycans as risk markers for non-small cell lung cancer

L. Renee Ruhaak, Carol Stroble, Jianliang Dai, Matt Barnett, Ayumu Taguchi, Gary E. Goodman, Suzanne Miyamoto, David R Gandara, Ziding Feng, Carlito B Lebrilla, Samir Hanash

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Previous studies have suggested occurrence of altered serum glycan profiles in patients with lung cancer. Here, we aimed to determine the predictive value of serum glycans to distinguish non-small cell lung cancer (NSCLC) cases from controls in prediagnostic samples using a previously validated predictive protein marker pro-SFTPB, as anchor. Blinded prediagnostic serum samples were obtained from the Carotene and Retinol Efficacy Trial (CARET), and included a discovery set of 100 NSCLC cases and 199 healthy controls. A second test set consisted of 108 cases and 216 controls. Cases and controls were matched for age at baseline (5-year groups), sex, smoking status (current vs. former), study enrollment cohort, and date of blood draw. Serum glycan profiles were determined by mass spectrometry. Twelve glycan variables were identified to have significant discriminatory power between cases and controls in the discovery set (AUC > 0.6). Of these, four were confirmed in the independent validation set. A combination marker yielded AUCs of 0.74 and 0.64 in the discovery and test set, respectively. Four glycan variables exhibited significant incremental value when combined with pro-SFTPB compared with pro-SFTPB alone with AUCs of 0.73, 0.72, 0.72, and 0.72 in the test set, indicating that serum glycan signatures have relevance to risk assessment for NSCLC.

Original languageEnglish (US)
Pages (from-to)317-323
Number of pages7
JournalCancer Prevention Research
Volume9
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Polysaccharides
Serum
Area Under Curve
Carotenoids
Vitamin A
Lung Neoplasms
Mass Spectrometry
Cohort Studies
Smoking
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ruhaak, L. R., Stroble, C., Dai, J., Barnett, M., Taguchi, A., Goodman, G. E., ... Hanash, S. (2016). Serum glycans as risk markers for non-small cell lung cancer. Cancer Prevention Research, 9(4), 317-323. https://doi.org/10.1158/1940-6207.CAPR-15-0033

Serum glycans as risk markers for non-small cell lung cancer. / Ruhaak, L. Renee; Stroble, Carol; Dai, Jianliang; Barnett, Matt; Taguchi, Ayumu; Goodman, Gary E.; Miyamoto, Suzanne; Gandara, David R; Feng, Ziding; Lebrilla, Carlito B; Hanash, Samir.

In: Cancer Prevention Research, Vol. 9, No. 4, 01.04.2016, p. 317-323.

Research output: Contribution to journalArticle

Ruhaak, LR, Stroble, C, Dai, J, Barnett, M, Taguchi, A, Goodman, GE, Miyamoto, S, Gandara, DR, Feng, Z, Lebrilla, CB & Hanash, S 2016, 'Serum glycans as risk markers for non-small cell lung cancer', Cancer Prevention Research, vol. 9, no. 4, pp. 317-323. https://doi.org/10.1158/1940-6207.CAPR-15-0033
Ruhaak LR, Stroble C, Dai J, Barnett M, Taguchi A, Goodman GE et al. Serum glycans as risk markers for non-small cell lung cancer. Cancer Prevention Research. 2016 Apr 1;9(4):317-323. https://doi.org/10.1158/1940-6207.CAPR-15-0033
Ruhaak, L. Renee ; Stroble, Carol ; Dai, Jianliang ; Barnett, Matt ; Taguchi, Ayumu ; Goodman, Gary E. ; Miyamoto, Suzanne ; Gandara, David R ; Feng, Ziding ; Lebrilla, Carlito B ; Hanash, Samir. / Serum glycans as risk markers for non-small cell lung cancer. In: Cancer Prevention Research. 2016 ; Vol. 9, No. 4. pp. 317-323.
@article{1fe7e7d25bc349188dc5202bf24fef10,
title = "Serum glycans as risk markers for non-small cell lung cancer",
abstract = "Previous studies have suggested occurrence of altered serum glycan profiles in patients with lung cancer. Here, we aimed to determine the predictive value of serum glycans to distinguish non-small cell lung cancer (NSCLC) cases from controls in prediagnostic samples using a previously validated predictive protein marker pro-SFTPB, as anchor. Blinded prediagnostic serum samples were obtained from the Carotene and Retinol Efficacy Trial (CARET), and included a discovery set of 100 NSCLC cases and 199 healthy controls. A second test set consisted of 108 cases and 216 controls. Cases and controls were matched for age at baseline (5-year groups), sex, smoking status (current vs. former), study enrollment cohort, and date of blood draw. Serum glycan profiles were determined by mass spectrometry. Twelve glycan variables were identified to have significant discriminatory power between cases and controls in the discovery set (AUC > 0.6). Of these, four were confirmed in the independent validation set. A combination marker yielded AUCs of 0.74 and 0.64 in the discovery and test set, respectively. Four glycan variables exhibited significant incremental value when combined with pro-SFTPB compared with pro-SFTPB alone with AUCs of 0.73, 0.72, 0.72, and 0.72 in the test set, indicating that serum glycan signatures have relevance to risk assessment for NSCLC.",
author = "Ruhaak, {L. Renee} and Carol Stroble and Jianliang Dai and Matt Barnett and Ayumu Taguchi and Goodman, {Gary E.} and Suzanne Miyamoto and Gandara, {David R} and Ziding Feng and Lebrilla, {Carlito B} and Samir Hanash",
year = "2016",
month = "4",
day = "1",
doi = "10.1158/1940-6207.CAPR-15-0033",
language = "English (US)",
volume = "9",
pages = "317--323",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Serum glycans as risk markers for non-small cell lung cancer

AU - Ruhaak, L. Renee

AU - Stroble, Carol

AU - Dai, Jianliang

AU - Barnett, Matt

AU - Taguchi, Ayumu

AU - Goodman, Gary E.

AU - Miyamoto, Suzanne

AU - Gandara, David R

AU - Feng, Ziding

AU - Lebrilla, Carlito B

AU - Hanash, Samir

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Previous studies have suggested occurrence of altered serum glycan profiles in patients with lung cancer. Here, we aimed to determine the predictive value of serum glycans to distinguish non-small cell lung cancer (NSCLC) cases from controls in prediagnostic samples using a previously validated predictive protein marker pro-SFTPB, as anchor. Blinded prediagnostic serum samples were obtained from the Carotene and Retinol Efficacy Trial (CARET), and included a discovery set of 100 NSCLC cases and 199 healthy controls. A second test set consisted of 108 cases and 216 controls. Cases and controls were matched for age at baseline (5-year groups), sex, smoking status (current vs. former), study enrollment cohort, and date of blood draw. Serum glycan profiles were determined by mass spectrometry. Twelve glycan variables were identified to have significant discriminatory power between cases and controls in the discovery set (AUC > 0.6). Of these, four were confirmed in the independent validation set. A combination marker yielded AUCs of 0.74 and 0.64 in the discovery and test set, respectively. Four glycan variables exhibited significant incremental value when combined with pro-SFTPB compared with pro-SFTPB alone with AUCs of 0.73, 0.72, 0.72, and 0.72 in the test set, indicating that serum glycan signatures have relevance to risk assessment for NSCLC.

AB - Previous studies have suggested occurrence of altered serum glycan profiles in patients with lung cancer. Here, we aimed to determine the predictive value of serum glycans to distinguish non-small cell lung cancer (NSCLC) cases from controls in prediagnostic samples using a previously validated predictive protein marker pro-SFTPB, as anchor. Blinded prediagnostic serum samples were obtained from the Carotene and Retinol Efficacy Trial (CARET), and included a discovery set of 100 NSCLC cases and 199 healthy controls. A second test set consisted of 108 cases and 216 controls. Cases and controls were matched for age at baseline (5-year groups), sex, smoking status (current vs. former), study enrollment cohort, and date of blood draw. Serum glycan profiles were determined by mass spectrometry. Twelve glycan variables were identified to have significant discriminatory power between cases and controls in the discovery set (AUC > 0.6). Of these, four were confirmed in the independent validation set. A combination marker yielded AUCs of 0.74 and 0.64 in the discovery and test set, respectively. Four glycan variables exhibited significant incremental value when combined with pro-SFTPB compared with pro-SFTPB alone with AUCs of 0.73, 0.72, 0.72, and 0.72 in the test set, indicating that serum glycan signatures have relevance to risk assessment for NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84964034061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964034061&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-15-0033

DO - 10.1158/1940-6207.CAPR-15-0033

M3 - Article

C2 - 26813970

AN - SCOPUS:84964034061

VL - 9

SP - 317

EP - 323

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 4

ER -